Adam Pavlicek, PhD


Dr. Adam Pavlicek started his interdisciplinary training at the Charles University, Prague, where he received an M.S. in Theoretical Biology. He followed with a Ph.D. in Human Genetics from the Jacques Monod Institute in Paris. In 2006, Dr. Pavlicek joined Pfizer Oncology, where he focused on identification of new cancer targets and discovery of predictive biomarkers of drug response from multidimensional omics data. He contributed to biomarker and patient selection strategies for several late stage projects including palbociclib (IBRANCE®), crizotinig (Xalcori®), as well as Aurora, Ang2, IGF1R, and gamma-secretase inhibitors. After that, he joined Regulus Therapeutics initially as a head of bioinformatics and more recently served as Senior Director of Discovery Technologies and Orphan Diseases. At Regulus, Dr. Pavlicek’s responsibilities included discovery and validation of novel microRNA targets.

Throughout his career, Dr. Pavlicek has acquired substantial expertise in drug discovery including broad expertise in many therapeutic areas including oncology, rare diseases, and disorders of liver, kidney, CNS, and eye. Dr. Pavlicek has published 50 original scientific articles and reviews, including articles in Clinical Cancer Research, JNCI, Lancet, Trends in Genetics, Genome Research, PLoS Biology, and PNAS. He is the founder and CEO of Monoceros Biosystems, and advisor for multiple drug discovery companies.